Refractory Tumor
15
1
2
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.3%
2 terminated out of 15 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (15)
A Study of DCR-STAT3 in Adults With Solid Tumors
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Neoantigen Derived DCs as Cancer Treatment
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Efficacy and Safety of Precision Therapy in Refractory Tumor
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077